Sotera Health (SHC) FY2024 results: revenue $1.1 billion, up 4.9% on the year

Sotera Health Co. (SHC) reported revenue of $1.1 billion for fiscal 2024, the year ended 31 December 2024, up 4.9% on the year before. Net income was $44 million, down 13.6%, and diluted earnings per share $0.16. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2025.

Revenue

$1.1 billion

+4.9% on the year

FY2019FY2024

Operating margin

27.0%

26.4% a year earlier

FY2019FY2024

Net income

$44 million

-13.6% on the year

FY2019FY2024

Diluted EPS

$0.16

-11.1% on the year

FY2019FY2024

this yearthe year beforeHover a bar for its figure.

The year in brief

The four quarters: Q1 FY2024 · Q2 FY2024 · Q3 FY2024 · Q4 FY2024

Income statement (profit and loss)

$ million	FY2024	FY2023	FY2022	On the year
Revenue	1,100	1,049	1,004	+4.9%
Cost of revenue	498	472	447	+5.5%
Gross profit	602	577	557	+4.4%
Gross margin	54.7%	55.0%	55.5%
Selling, general and administrative	243	237	246	+2.5%
Operating income	298	277	248	+7.6%
Operating margin	27.0%	26.4%	24.7%
Pre-tax income	114	106	-243	+7.4%
Income tax	69.5	54.7	-9.5	+27.1%
Effective tax rate	61.0%	51.5%	n/a
Net income	44.4	51.4	-234	-13.6%
Net margin	4.0%	4.9%	-23.3%
Diluted EPS	$0.16	$0.18	-$0.83	-11.1%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	FY2024	FY2023	FY2022	On the year
Operating cash flow	224	-148	278
Capital expenditure	179	215	182	-16.7%
Free cash flow	45.1	-363	95.6
Free cash flow margin	4.1%	-34.6%	9.5%
Cash from investing	-179	-215	-182
Cash from financing	-50.6	266	198
Depreciation and amortisation	84.3	76.6	64.3	+10.1%
Share-based compensation	36.8	32.2	21.2	+14.1%
Buybacks	n/a	n/a	0.0
Diluted shares, weighted	285m	283m	280m	+0.6%

Balance sheet

$ million	FY2024	FY2023	FY2022	On the year
Shareholders' equity	405	444	350	-8.7%
Non-controlling interest	n/a	n/a	0.0
Debt	2,223	2,228	1,944	-0.2%
Operating lease liabilities	24.5	20.1	21.6	+21.8%
Finance lease liabilities	95.3	63.8	57.0	+49.4%
Other liabilities	324	374	745	-13.4%
Total liabilities and equity	3,072	3,130	3,118	-1.9%
Fixed assets	n/a	n/a	775
Goodwill	1,081	1,111	1,102	-2.7%
Intangible assets	318	416	491	-23.7%
Cash and equivalents	277	296	395	-6.5%
Receivables	140	148	118	-5.0%
Inventory	49.2	48.3	37.1	+1.7%
Other assets	1,206	1,110	199	+8.6%
Total assets	3,072	3,130	3,118	-1.9%

10-K for the year ended 31 December 2024, filed 27 February 2025: the filing.